New Research Facility

Aortech International PLC 28 August 2001 AORTECH INTERNATIONAL PLC New Melbourne Research Laboratory AorTech International plc, the Scottish-based manufacturer of cardio-vascular devices, announces that it today opened a new research laboratory in Melbourne, Australia. The facility will support the commercialisation of its novel biomaterials, Elast-EONTM, which is used in synthetic heart valves, pacemakers and other medical devices. The global market for these medical devices is forecast to grow from US$10 billion in 1999 to nearly US$15 billion by 2005. The current global market for heart valves alone is estimated at US$800 million. AorTech Biomaterials Pty Ltd, (formally known as Elastomedic P/L), which is based in Melbourne and Sydney has developed a special formulation based on its revolutionary Elast-EonTM polymeric product on which the next generation of heart valves will be constructed. The Company's breakthrough in the polymer involves a unique blend of silicone with polyurtherane that ensures a more durable, tear resistant and highly flexible material that allows the development of smaller and more effective implantable devices. The revolutionary range of biomaterials was developed by a team of researchers at CSIRO's Molecular Science laboratory in Melbourne as part of the Cooperative Research Centre (CRC) for Cardiac Technology. The organisation's enabling technologies have taken more than 10 years to develop fully. Dr Mike Skalsky, Managing Director of AorTech Biomaterials commented: 'The AorTech heart valve is in the final stage of development and will shortly be entering the regulatory testing stage prior to clinical trials in patients in the latter half of 2002. This new polymer synthesis laboratory will greatly enhance the progress of this and other company projects.' For further details go to AorTech Biomaterials its website at: www.aortechbio.com 28th August 2001 ENQUIRIES: Aortech International plc Tel: 01698 746 699 Eddie McDaid, Chief Executive College Hill Tel: 020 7457 2020 Michael Padley Nicholas Nelson
UK 100

Latest directors dealings